IMPROVE observational program: safety and effectiveness of biphasic insulin aspart 30 in routine clinical practice. Overview of starting characteristics of the Russian patient cohort
AIM: To analyse starting characteristics of the Russian patient cohort included in the IMPROVE observational program with reference to its demographiccomposition and clinical features of the disease in patients allocated to different groups depending on previous treatment, reason for prescribing DiA...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN RU |
| Publicado: |
Endocrinology Research Centre
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5559038c5c01444990377c7ad5906eb9 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | AIM: To analyse starting characteristics of the Russian patient cohort included in the IMPROVE observational program with reference to its demographiccomposition and clinical features of the disease in patients allocated to different groups depending on previous treatment, reason for prescribing DiAsp 30 (NovoMix 30) therapy, and its initial dosage regime.
METHODS: The analysis covered the cohort of Russian patients included in the IMPROVE global program, an open non-randomizedobservational multicentre study of safety and effectiveness of insulin DiAsp for patients with DM2 during 26 weeks of routine clinical practice. In thepreceding period, the patients (n=4869) received either oral hypoglycemic agents (OHAs) (n=2430) or insulin +/- OHAs (n=2343); the controlgroup was comprised of 95 patients given no previous antidiabetic treatment.
RESULTS: Most patients had inadequate glycemic control prior to DiAsp therapy with the mean HbA1c level of 9,2%. Those given no previous antidiabetictreatment showed the highest HbA1c level (9,9%) and higher frequency of microvascular vs macrovascular complications (91 and 51% respectively).Patients that used the largest amount of antidiabetic agents developed the highest number of complications; this situation reflects therelationship between poor glycemic control and the risk of complications.
CONCLUSIONS: The Russian patient cohort is one of the three largest ones in the IMPROVE? global program. They reside in different geographic regions,have different history of antidiabetic treatment and far-from-normal HbA1c levels as a result of altogether poor glycemic control in Russian patientswith DM2. The cohort at large exhibits a suboptimal HbA1c level even though the majority of the patient have an access to antidiabetic therapy. Mostphysicians participating in the study refer to improved glycemic control in their DM2 patients (lowered HbA1c, fasting and postprandial glucose levels)as the main reason for the initiation of therapy with DiAsp 30 (NovoMix 30). |
|---|